These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1732628)

  • 41. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
    Ratliff TL; Kavoussi LR; Catalona WJ
    J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
    Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
    Muto S; Nakajima A; Horiuchi A; Inoue M; China T; Saito K; Isotani S; Hisasue S; Yamaguchi R; Ide H; Horie S
    Jpn J Clin Oncol; 2013 Mar; 43(3):305-13. PubMed ID: 23303841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Production of tumor necrosis factor by intravesical administration of bacillus Calmette Guérin in patients with superficial bladder cancer.
    Kim CI; Shin JS; Kim HI; Lee JM; Kim SJ
    Yonsei Med J; 1993 Dec; 34(4):356-64. PubMed ID: 8128741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration.
    Hudson MA; Catalona WJ; Ritchey JK; Aslanzadeh J; Brown EJ; Ratliff TL
    J Urol; 1989 Dec; 142(6):1438-41. PubMed ID: 2585615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defective antiadherence activity of bladder extracts from patients with recurrent urinary tract infection.
    Ruggieri MR; Levin RM; Hanno PM; Witkowski BA; Gill HS; Steinhardt GF
    J Urol; 1988 Jul; 140(1):157-9. PubMed ID: 3379683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
    Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rabbit bladder-surface mucin: a thermodynamic mechanism for inhibiting bacterial adhesion.
    Boyce JF; Podesta RB; Schürch S; Roach MR
    Urol Res; 1983; 11(2):93-5. PubMed ID: 6868223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Escherichia coli adherence to anion exchange resin. In vitro model for initial screening of potential antiadherence agents.
    Ruggieri MR; Hanno PM; Levin RM
    Urology; 1986 Apr; 27(4):343-8. PubMed ID: 3083556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
    Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
    J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
    Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
    J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.